# AN2 Therapeutics, Inc.

Canonical: https://abierto.us/vendors/an2-therapeutics-inc-dd4fe2ge4l78

- UEI: DD4FE2GE4L78
- CAGE: 822Z2
- Location: Menlo Park, CA
- Awards in window: 1 (9 transactions), $4,278,131 obligated, March 1, 2024 to August 18, 2026

## Awarding agencies

- National Institutes of Health: 1 awards, $4,278,131

## Industries

- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $4,278,131

## Competition

- Full and Open Competition: 1 awards

## Largest awards

- 75N93022C00059 (definitive contract): $4,278,131, National Institutes of Health Niaid. Development of Epetraborole as a Novel Therapeutic for Melioidosis and Additional Antimicrobial Resistant (Amr) Bacterial Biothreat Pathogens.. https://www.usaspending.gov/award/CONT_AWD_75N93022C00059_7529_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/an2-therapeutics-inc-dd4fe2ge4l78.